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Standardized extract from the leaves of the Ginkgo biloba tree,
labeled EGb761, has been used in clinical trials for its beneficial
effects on brain functions, particularly in connection with age-
related dementias and Alzheimer’s disease (AD). Substantial ex-
perimental evidence indicates that EGb761 protects against neu-
ronal damage from a variety of insults, but its cellular and
molecular mechanisms remain unknown. Using a neuroblastoma
cell line stably expressing an AD-associated double mutation, we
report that EGb761 inhibits formation of amyloid- (A) fibrils,
which are the diagnostic, and possibly causative, feature of AD.
The decreased A fibrillogenesis in the presence of EGb761 was
observed both in the conditioned medium of this A-secreting cell
line and in solution in vitro. In the cells, EGb761 significantly
attenuated mitochondrion-initiated apoptosis and decreased the
activity of caspase 3, a key enzyme in the apoptosis cell-signaling
cascade. These results suggest that (i) neuronal damage in AD
might be due to two factors: a direct A toxicity and the apoptosis
initiated by the mitochondria; and (ii) multiple cellular and molec-
ular neuroprotective mechanisms, including attenuation of apo-
ptosis and direct inhibition of A aggregation, underlie the neu-
roprotective effects of EGb761.
Extracts of Ginkgo biloba leaves have been marketed astherapeutic dietary supplements to counteract a variety of
neurological disorders, including Alzheimer’s disease (AD) (1).
Substantial experimental evidence indicates that Ginkgo extracts
have neuroprotective effects in animals and humans (2); how-
ever, the cellular and molecular mechanisms remain unclear (3).
There is much to be learned about the pathophysiology of the
disease and, importantly, about possible novel therapeutic ap-
proaches from analyzing the pharmacological mechanisms of
this traditional remedy.
Autosomal dominant forms of AD appear to be caused by
deposition of insoluble amyloid  (A), a proteolytic fragment
of 40–42 amino acid residues derived from amyloid precursor
protein (APP), in the brain (4, 5). Mutations in APP and
presenilins (PS1, PS2), associated with familial AD, increase the
production of the total A or the more amyloidogenic form
A42 (6). Accumulating experimental evidence suggests links
between deposition of A, oxidative stress, and apoptosis asso-
ciated with AD (7) and aging (8). The A peptide has been
shown to induce apoptosis in neurons, which may contribute to
the neuronal degeneration in AD (9). Brain tissue from AD
patients contains deposits of oxidized A (10) and activated
caspase-3, a cysteine protease that mediates mitochondrion-
initiated apoptosis (11). Other members of the caspase family
have been found to mediate apoptosis resulting from A cyto-
toxicity (12). These findings suggest potential pharmacological
targets that can be used in strategies aimed at slowing the
progression of neuronal loss in AD. The goal of the present work
was to study the protective mechanisms of the standardized
extract EGb761 against A-induced apoptosis by using
well-established methods of cell and molecular biology and
biochemistry. We report that the mouse neuroblastoma cell line
expressing double-mutated human APP and PS1 exhibits A
aggregation and activation of caspase 3. Both the A aggregation
and the caspase-3 activity were inhibited by treatment with
EGb761. Furthermore, EGb761 interacted directly with A and
had a profound inhibitory effect on the formation of A fibrils.
These results suggest that EGb761 provides a combination of
antioxidive, antiamyloidogenic, and antiapoptotic effects, which
can all be potentially used in the treatment andor prevention
of AD.
Materials and Methods
Reagents. The standardized Ginkgo biloba leaf extract EGb761
used in the clinical trials (2) was from Schwabe Pharmaceuticals
(Karlsruhe, Germany). The main active components are flavone
glycosides (24%) and terpene lactones (6%), which include the
ginkgolides and the bilobalide (1). The ginkgolides A, B, C, and
J and the bilobalide B were isolated as described (13). A1–40 was
purchased from Sigma or W. M. Keck Biotechnology (New
Haven, CT). Antibodies to A17–24 (4G8, which is specific for A
and APP), and A1–17 (6E10, which recognizes A and also
APPs), were from Signet Laboratories (Dedham, MA). Anti-
body to A1–5 (3D6) was provided by Athena Neurosciences
(San Diego). The caspase-3 activity assay kit was from Biomol
(Plymouth Meeting, PA). Other chemicals were from Sigma.
Cell Lines. The N2a neuroblastoma control cells [wild type (wt)]
or the N2a cell line stably expressing Swedish mutant APP695
and the exon-9 deletion mutant PS1 (swe9) were maintained,
as described (14, 15), in the medium containing 50% DMEM and
50% Opti-MEM, supplemented with 5% FBS, 200 gml of
G418, and other antibiotics (GIBCO). The expression of the
transgenes was induced by the addition of 1 M butyric acid
(sodium salt) for 12 h in a 1% serum medium.
Fibrillogenesis of Purified A by Using an in Vitro Fluorescence Assay.
A was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol and son-
icated in a bath sonicator to produce a concentrated stock (4.6
mM) of the monomeric peptide (16). The peptide was diluted
with PBS to 46 M and incubated at room temperature for 96 h.
To measure the EGb761 effects, the peptide was mixed with
EGb761 (100 gml) or its components bilobalide B, ginkgolides
A, B, C or J (29 gml). Aliquots were transferred into the
measuring solution (5 mM thioflavin T50 mM glycine-NaOH
buffer, pH 8.5). Fluorescence was measured within 5 s in a
Hitachi F-2000 spectrofluorometer with the excitation and
emission wavelengths of 435 and 485 nm, respectively (17).
Electron and Immunoelectron Microscopy. An aqueous suspension
of aggregated A was incubated on formvar-coated nickel grids
Abbreviations: AD, Alzheimer’s disease; A, amyloid ; APP, amyloid precursor protein; PS,
presinilin; wt, wild type.
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for 20 min and negatively stained with 1% phosphotungstic acid
(adjusted to pH 7.0). For immunolabeling of A fibrils in cell
culture, the conditioned media were collected and centrifuged at
12,000  g for 20 min. The pellets were resuspended in 20 l of
water and incubated on the grids for 20 min. The grids were
washed (150 mM NaCl5 mM TrisHCl, pH 7.4), blocked with
BSA, incubated with an anti-A antibody (4G8, 1:300 dilution),
and rinsed. Goat anti-mouse IgG antibody conjugated with gold
particles (diluted 1:40, Electron Microscopy Sciences, Fort
Washington, PA) was applied, followed by rinsing and fixing with
2% glutaraldehyde. Samples were negatively stained with phos-
photungstic acid and examined by using a Zeiss 109-T transmis-
sion electron microscope (Leo Electron Microscopy, Thorn-
wood, NY).
Immunoblotting of A Aggregation in Solution and Cell Culture
Media. Purified A (40 M) was incubated either alone or in the
presence of EGb761 (100 gml) for 24 h or 8 days at room
temperature. Proteins were separated by SDSPAGE on a
ready-made 4–20% gradient acrylamide gel (Bio-Rad). A con-
trol lane contained freshly prepared A peptide. The A species
were identified by immunoblotting by using the antibody 6E10
and the standard Western blotting protocol. For detecting A
species in culture medium, transgene expression in the control
(wt) or mutant cells (swe9), preincubated with or without
EGb761 for 48 h, was induced with butyric acid overnight. The
media were then collected and immunoprecipitated with the
antibody 3D6, followed by Western blotting with the antibody
6E10.
Apoptosis Assay by Mitochondrial Staining. The integrity of the
mitochondria was tested with an ApoAlert staining kit (CLON-
TECH), which uses a proprietary dye mixture called Mitosensor,
whose fluorescence exhibits spectral shift in apoptotic cells. In
healthy cells, the dye is taken up in the mitochondria, where it
forms aggregates that fluoresce bright red. In apoptotic cells, a
shift in the mitochondrial membrane potential prevents the dye
from accumulating in the mitochondria. It remains as monomers
in the cytoplasm, where it f luoresces green. The control (wt) and
mutant cells (swe9) were cultured on coverslips in 6-well
plates and grown to approximately 60% confluency in 5% CO2
at 37°C. The cells were treated with EGb761 (100 gml) or
vitamin E (25 M) 48 h before induction of expression. The A
expression was induced by addition of 1 M butyric acid. After
12 h, the cells were gently washed with serum-free medium and
incubated with the Mitosensor dye for 20 min at 37°C. The
stained coverslips were inverted, mounted onto glass slides, and
examined with a fluorescence microscope (Olympus BX60,
Tokyo). The images were captured by a camera and processed
with PHOTOSHOP 5.5 (Adobe Systems, Mountain View, CA).
Analysis of Cell Death. Cell death was quantified by the trypan blue
exclusion method. Cells were grown in a 96-well plate to a density
of about 2,000 cellwell, untreated or treated with EGb761 for
48 h, washed with PBS, and stained with 0.1% trypan blue for 15
min. After another wash, 0.1 M NaOH was added, and the dye
uptake by the cells was quantified at 562 nm in a microtiter plate
reader (BioTek, Winooski, VT).
Caspase-3 Activity Assay. A quantitative enzymatic activity assay
was carried out according to instructions of the Biomol colori-
metric assay kit manufacturer. After drug treatment, cells were
washed with ice-cold PBS, lysed, centrifuged, and analyzed for
total protein by the Bradford assay. Samples containing 50 g of
total protein were assayed for caspase-3 activity with Ac-DEVD
as a caspase-3-specific substrate. Absorbance was measured at
405 nm in a plate reader. For immunoblotting, equal amounts of
total protein from cell extract were subjected to SDSPAGE and
probed with an antibody specific for cleaved caspase 3 (Phar-
Mingen). Caspase-3 immunoreactivity was detected with a
chemiluminescence kit (Amersham Pharmacia). The blot was
stripped and reblotted with an antiactin antibody to prove that
all of the lanes were loaded with the same amount of protein.
Results
EGb761 Prevents A Aggregation in Vitro. To determine whether
EGb761 affects A fibrillogenesis, we first measured in vitro
aggregation of A in the absence and presence of EGb761 by the
thioflavin T method (17). The data in Fig. 1A show that EGb761
directly prevents A fibrillogenesis. In all controls (buffer,
EGb761 alone, and 46 M albumin as an irrelevant protein),
thioflavin T showed low constant fluorescence for the duration
of each experiment (data not shown). Assuming that the fluo-
rescence intensity is proportional to the extent of A aggrega-
tion, the results indicate that 100 gml of EGb761 inhibits
aggregation by 82  6% (average  SEM, n  4, P  0.0014 by
the unpaired two-tailed t test). The inhibition by EGb761
appears to be thermodynamic rather than kinetic, because it
could not be overcome by very long incubations (up to 1 mo).
In an attempt to determine ID50, the concentration required
for a 50% inhibition of A aggregation, assays were performed
with 0, 1, 4, 10, 20, and 100 gml of EGb761. Significant
inhibition was observed only at the highest concentration, indi-
cating that the ID50 value is between 20 and 100 gml.
Several individual constituents of EGb761 were tested for
their ability to inhibit A aggregation in vitro by the same assay.
Each component was used at an arbitrary concentration of 29
gml, which is higher than that expected in the whole extract
(maximum 6 gml in 100 gml of EGb761). The higher
concentrations were used because in these experiments, the
individual components cannot exhibit synergism, which is often
postulated in the action of the whole EGb761. Inhibition of
aggregation comparable to that obtained with the whole extract
was observed with bilobalide (73%) and ginkgolide J (72%).
Ginkgolides A, B, and C had much smaller effects: 35, 20, and
42%, respectively.
To confirm the thioflavin T data by an alternative method, A
fibrillogenesis was assessed by electron microscopy (Fig. 1B) and
Western blotting (Fig. 1C). When freshly prepared A peptide
was incubated with or without EGb761 as described above, a
significant difference was observed between the two prepara-
tions. A incubated with EGb761 exhibited electron-dense
disordered aggregates (Fig. 1Bb) but not the characteristic fibrils
that were observed in the absence of EGb761 (Fig. 1Ba). These
results were confirmed by Western blotting with the antibody
6E10 (Fig. 1C). The aggregated A was present in the form of
oligomers (nA), presumably dimers or trimers, according to the
molecular-weight standards. More dimers were observed after
longer incubation times (Fig. 1C, lane 4 vs. 2). EGb761 consis-
tently prevented A dimer formation even at the long incubation
time (Fig. 1C, lane 4 vs. 5).
EGb761 Prevents A Aggregation in the Medium of A-Producing
Cells. To further confirm the antifibrillogenic activity of EGb761
in a cell system, immunoelectron microscopy was used to search
for A fibrils in the media of the N2a wt and swe9 cells.
Culture medium of the swe9 cells probed only with the
secondary antibody showed a little gold deposition due to a low
level of nonspecific binding (data not shown). As a positive
control, purified A was incubated for 48 h as described above
and incubated with the monoclonal antibody 4G8 and a gold-
conjugated secondary antibody. Fig. 2Aa shows that gold-labeled
fibrils were present in this preparation. Similar immunoreactive
fibrils were observed in the medium recovered from swe9 cells
(Fig. 2 Ac) but not in the medium from N2a wt cells (Fig. 2 Ab),
which showed a level of gold labeling comparable to the negative
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control. Importantly, labeled fibrils were not detected in swe9
cells treated with EGb761 (Fig. 2 Ad), indicating that EGb761
prevented A fibril formation in the cell culture. Similar results
were obtained with three independent preparations.
Immunochemical labeling of A (Fig. 2B) further supported
this finding. Cell culture media from the N2a and swe9 cells,
untreated or treated with EGb761, were collected and immu-
noprecipitated with the antibody 3D6, followed by Western
blotting with the antibody 6E10. There was no detectable A
immunoreactivity in the medium from the N2a cells (Fig. 2B,
lanes 2 and 3 vs. 1). In contrast, an aggregated A band (nA),
at a molecular mass between 7 and 21 kDa (Fig. 2B, lane 4),
presumably dimers or higher oligomers, was detected in the
culture medium of the swe9 mutant cells. Most obviously, the
Fig. 1. In vitro A fibrillogenesis in the presence or absence of EGb761. (A)
Thioflavin T fluorescence assay. A (46 M) was incubated in the absence
(control) or presence of 100 gml of EGb761 (EGb), or 29 gml of bilobalide
(BB) or ginkgolides A, B, C, and J (GA, GB, GC, and GJ, respectively) for 96 h at
room temperature. The whole extract EGb761 was tested in four independent
experiments, the difference was statistically significant: P  0.0014 by the
unpaired two-tailed t test. The individual components were only tested once,
therefore no variability or statistical significance is given. (B) Electron micros-
copy. A peptide was incubated overnight either alone (a) or with 100 gml
of EGb761 (b) and examined by electron microscopy. (Bar  100 nm.) The
results were qualitatively reproduced in three independent experiments. (C)
Immunoblotting of A species using the antibody 6E10. Lane 1, freshly pre-
pared A; lanes 2 and 3, A incubated without or with EGb761 for 24 h,
respectively; lanes 4 and 5, A incubated without or with EGb761 for 8 days,
respectively. Arrows indicate A monomers (A) or oligomers (nA).
Fig. 2. A fibrillogenesis in mutant neuroblastoma cells in the presence or
absence of EGb761. (A) Immunoelectron microscopy of A fibrils in culture
media. (a) In vitro aggregated A immunolabeled with the antibody 4G8; (b)
the wt cell culture medium collected and immunolabeled with 4G8; (c) the
swe9 cell culture medium collected and probed with 4G8; (d) the culture
medium collected from swe9 cells treated with EGb761 for 48 h and probed
with 4G8. a–d represent areas of several grids in three separate experiments.
(B) Immunoblotting of A species from the culture media of neuroblastoma
cells: purified A (lane 1); wt untreated (wt, lane 2) or treated with 100 gml
of EGb761 for 48 h (wt  EGb, lane 3); mutant cell line untreated (swe9, lane
4) or treated with 100 gml of EGb761 for 48 h (swe9  EGb, lane 5).
Arrows indicate A monomer (A) or aggregated oligomers (nA). The blot
represents three independent experiments.








A oligomer band (nA) was absent in the medium recovered
from cells treated with EGb761 (Fig. 2B, lane 5), demonstrating
that EGb761 inhibited A fibril formation. EGb761 had no
effect on A production, nor did it affect the levels of APPs,
a product of  secretase, or total cellular APP (data not shown).
Hence, the EGb761-induced attenuation of A fibrillogenesis is
not because of an overall inhibition of A production.
EGb761 Attenuates Mitochondrion-Sensitive Neurotoxicity and
Caspase-3 Activity in Neuroblastoma Cells. To provide a possible
link between endogenous A production and apoptosis activa-
tion, cell viability in A-producing neuroblastoma cells express-
ing mutated APP and PS1 was first measured by Mitosensor. Fig.
3A demonstrates that the swe9 cells f luoresced green after
induction of transgene expression, indicating mitochondrion-
initiated apoptosis (Fig. 3Aa), whereas N2a wt cells showed red
fluorescence indicative of healthy mitochondria (Fig. 3Ab). The
apoptosis in swe9 cells was attenuated by treatment with
EGb761 for 48 h before induction of expression (Fig. 3Ac). As
a comparison, vitamin E, a known antioxidant, attenuated
apoptosis to a lesser degree (Fig. 3Ad). Cell viability measured
by trypan blue exclusion confirmed this observation quantita-
tively (Fig. 3B). Both N2a wt and mutant (swe9) exhibited
vulnerability after stimulation with butyric acid to induce trans-
gene expression. However, cell death in the mutant was 2-fold
higher than that in the wt, and in both cases EGb761 attenuated
it. In the N2a wt cells, the EGb761 attenuation was not statis-
tically significant (P  0.098, n  6), but in the mutant it was (P 
0.0015, n  6).
Fig. 3. Mitochondrion-sensitive A cytotoxicity in the mutant cells untreated
or treated with EGb761. (A) Representative fluorescence staining for apopto-
sis in the swe9 cells with and without drug treatments. Mitochondrial
integrity was probed by using Mitosensor (see Materials and Methods).
Mitochondria of healthy cells exhibit red fluorescence, cells undergoing apo-
ptosis exhibit green fluorescence. (a) Mutant cells (swe9) stimulated with 1
M butyric acid for 12 h to express the transgene; (b) unstimulated wt N2a cells
(wt); (c) swe9 cells pretreated with EGb761 for 48 h; (d) swe9 cells
pretreated with vitamin E (VE) for 48 h. Similar results were obtained in three
experiments. (B) Cell death assay by using quantitative trypan blue exclusion.
wt or mutant (swe9) neuroblastoma cells were treated with 100 gml of
EGb761 for 48 h and stimulated with 1 M butyric acid to express the
transgene. Results are mean  SEM (n  6). EGb761 had a significant effect on
cell death in the mutant cell line (P  0.0015), but not the wt (P  0.098).
Fig. 4. Caspase-3 activity in neuroblastoma cells in the presence or absence
of EGb761. (A) Caspase-3 enzymatic activity assay in the N2a cells (wt), and the
swe9 (swe9) cells alone, or treated with EGb761 for 48 h. Data are
expressed as percentage of the maximum caspase-3 activity in swe9 cells,
which, in average, was equivalent to 1.6 pmolmg of proteinmin. *, statistical
significance (P  0.05, n  4) by unpaired t test. (B) Representative Western
blots of caspase-3 activation in the control and the mutant cells. Lane 1:
unstimulated N2a cells; lane 2: N2a cells stimulated with 1 M butyric acid for
12 h; lane 3: mutant cells stimulated with butyric acid for 12 h; lane 4: mutant
cells treated with 100 gml of EGb761 for 48 h before stimulation with
butyric acid; lane 5: N2a wt cells treated with 0.1 M A for 12 h; lane 6: N2a
cells treated with 100 gml of EGb761 for 48 h before treatment with 0.1 M
A for 12 h. Arrows indicate cleaved (activated) caspase 3 at about 17 kD. The
lower blot is an immunoblot of actin indicating that same amount of proteins
were loaded in each lane. Results are representative of two independent
experiments.
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Changes in the mitochondrial membrane potential lead to the
release of cytochrome c into the cytoplasm, caspase activation,
and apoptosis (18). Previous studies have indicated that mito-
chondrion-initiated apoptosis is mediated by caspase 3 (19, 20).
To determine whether caspase 3 was activated in the double
mutant, the enzymatic activity in the swe9 cells and the wt was
measured by both a quantitative colorimetric caspase-3 activity
assay (Fig. 4A) and Western blotting with an antibody specific for
activated caspase 3 (Fig. 4B). Caspase 3 was activated in both cell
types after stimulation with 1 M butyric acid but much less so
in wt (Fig. 4A, wt vs. wt  BA, P  0.05, n  4; swe9 vs.
swe9 BA, P  0.005, n  4, Fig. 4B, lanes 2 vs. 3). We
demonstrated unambiguously that the internally activated
caspase 3 in the mutant cells was significantly inhibited by pre-
treatment of the cells with EGb761 (swe9BA vs. swe9 
EGb  BA, P  0.05, n  4, Fig. 4B lane 3 vs. 4). The inhibition
of caspase 3 activity by EGb761 in the wt stimulated with butyric
acid was not significant (wt  BA vs. wt  EGb  BA, P  0.05,
n  4). Vitamin E, a known antioxidant, did not show significant
inhibition in the mutant (Fig. 4A, swe9  BA vs. swe9 
VE  BA, P  0.05, n  5). To support the notion that caspase-3
activation is due to expression of A in the mutant cells, purified
A was added to the culture medium of control N2a cells. The
cleaved 17-kDa caspase 3 was observed in this preparation (Fig.
4B, lane 5). Further, A-induced activation of caspase 3 was
attenuated by the treatment of the cells with EGb761 (Fig. 4B,
lane 6). Immunoblotting of the samples with antiactin (Fig. 4B
Lower) proves that equal amounts of protein were loaded in each
lane. These results strongly suggest that the apoptosis in the
cultured swe9 cells is mediated by caspase 3 and the protective
action of EGb761 may be carried out, at least in part, by
inhibition of caspase-3 activation.
Discussion
On the basis of numerous pharmacological studies with animals,
and more recently with humans, it has been proposed that
EGb761 ameliorates neurodegeneration associated with aging
(1, 2). This study was designed to investigate the effects of the
Ginkgo biloba extract EGb761 at the cellular and molecular
levels by using well-established methods of cell and molecular
biology and biochemistry. Our results demonstrate that EGb761
directly inhibits amyloid fibril formation in solution and in the
cell culture medium. We further demonstrate that EGb761
prevents amyloid neurotoxicity and inhibits caspase-3 activity in
cell culture.
A fibril formation is believed to be the main determinant in
the pathogenesis of AD, although it is not clear how A fibrils
exert their cytotoxic effects. There are reports that A fibrils
permeabilize lipid membranes (21) and induce calcium currents
(22) and other electrophysiological changes (23) in neurons.
Thus, inhibition of cerebral A aggregation is an important goal
in AD therapy. Several compounds have been reported to have
such an effect: melatonin (24), some nonsteroidal antiinflam-
matory drugs (25), sulfated mono- and disaccharides (26),
synthetic peptides (27, 28), and cerebrospinal-f luid proteins such
as thransthyretin (29). Because of the known relationship be-
tween oxidative stress and AD and because of the established
antioxidative properties of Ginkgo biloba, it has been proposed
that EGb761 exerts its neuroprotective effects mostly as an
intracellular antioxidant (1). However, results presented herein
suggest that the antiamyloidogenic property of EGb761 could be
a consequence of its direct interaction with A. The preventative
effect of EGb761 on in vitro formation of amyloid fibrils was
recently (while our work was in progress) reported by two other
laboratories (30, 31). Our results confirm these observations and
demonstrate the effect in a cellular system, namely, in the culture
medium of an A-producing cell line.
The EGb761 extract is a relatively complex mixture of com-
pounds. We attempted to address this issue by testing several
individual constituents of the terpenoid fraction of EGb761. In
vitro, bilobalide and ginkgolide J seem to be the most active
terpenoids in EGb761 (Fig. 1 A), consistent with the observed
effect of EGb761 constituents on caspase-3 activation in differ-
entiated PC12 cells (32). Ramassamy et al. (30) tested just one
terpenoid—ginkgolide B—and found it did not inhibit A
fibrillogenesis, which is confirmed in the present work (Fig. 1 A).
Instead, they suggest that the active components of EGb761 are
in the flavonoid fraction, which has not been included in the
present study.
A variety of effects of A on cells have been reported (33, 34),
including induction of cytotoxicity as well as apoptotic neuronal
death. In most of these studies, exogenous A was added to the
culture medium at much higher concentrations than physiolog-
ical. In the present study, a stably transfected A-producing
neuroblastoma cell line (swe9) was used (14), acting as the
source of endogenous A. We found that caspase-3 was activated
in these cells after the expression of the transgene. The present
work demonstrates constitutively increased caspase-3 activity in
the N2a cells expressing mutated human APP and PS1. Apart
from the implications for understanding A cytotoxicity, this
finding is an important contribution to the characterization of
this cell line.
Butyric acid has been known to induce cytotoxicity and
apoptosis in cells (35). Therefore, its use as an inducer of
transgene expression in our work deserves some discussion.
First, concentrations of butyric acid used to induce apoptosis are
usually in the millimolar range, whereas we used 1 M. Second,
although the wt cells did exhibit apoptosis when stimulated with
butyric acid (Fig. 4B, lane 2), it was much less than the mutant
cells (Fig. 4B, lane 3). The only significant difference between
the two cell lines is the production of the amyloidogenic A
peptide. Consequently, the increased apoptosis and caspase-3
activation in the swe9 cells must be because of the presence
of the endogenous A. When the control cells were incubated
with exogenous A, caspase 3 was also activated. Further, when
the mutant cells were incubated with a caspase-3 inhibitor before
the butyric acid stimulation, the activation of caspase 3 was
blocked (data not shown). The contribution of butyric acid to the
activation of caspase 3 in our system was not negligible. But,
interestingly enough, EGb761 inhibited caspase-3 activity in all
cases, irrespective of the activation mechanism, as demonstrated
in Fig. 4A. This observation suggests that, in addition to the
inhibition of A fibrillogenesis, EGb761 may act on the intra-
cellular signaling pathways.
The two best-studied pathways of caspase activation are the
cell-surface–death-receptor pathway, i.e., Fas-mediated apopto-
sis, and the mitochondrion-initiated pathway (36). The present
data show that A expression activates the key element of the
mitochondrion-initiated pathway. Although other recent studies
have suggested that caspases 2 and 12 mediate A-induced cell
death in several neuronal populations and in experimental
animals (28, 37), our data implicate another member of the
apoptosis-signaling cascade, caspase 3. It is possible that the AD
pathophysiology at the cellular level involves both direct A
toxicity and mitochondrial sensitization to the initiation of
apoptosis. The ability to attenuate the intrinsic caspase-3 acti-
vation in the AD-associated mutant cells by EGb761 suggests a
potential role for this herbal extract in AD therapy.
In summary, the results reported herein indicate that EGb761
exerts a combination of antioxidative, antiamyloidogenic, and
antiapoptotic effects. Our conclusion is consistent with the
recent result of a genome-wide monitoring of the biochemical
effects of herbal remedies in mice, in which the neuromodulatory
actions of Ginkgo biloba were pinpointed to many proteins that
are significantly overtranscribed in the hippocampus and cortex








(38). It is of a particular interest that the apoptosis-related genes
were either up- or down-regulated in PC12 cells treated with
EGb761 (32).
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